SCHEMBL6674592

SCHEMBL6674592

O=C(Nc1ccc(/C=C/c2ccccc2)cc1C(=O)O)c1cc(O)cc(O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.56
HNF4A P41235 1/20 0.56
PTGS2 P35354 1/20 0.51
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
MAPT P10636 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
AKR1C4 P17516 2/20 0.50
AKR1C3 P42330 2/20 0.50
AKR1C2 P52895 2/20 0.50
AKR1C1 Q04828 2/20 0.50
PKM P14618 2/20 0.50
GFER P55789 2/20 0.50
LTC4S Q16873 1/20 0.50
GRIK1 P39086 1/20 0.50
PTPN2 P17706 1/20 0.49
PTPN6 P29350 1/20 0.49
TOP2A P11388 1/20 0.48
TTR P02766 1/20 0.48
SERPINE1 P05121 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6675963 1.00 PTPN1 (0.56) PTPN1HNF4APTGS2MEN1KMT2A
SCHEMBL6674346 0.90 MEN1 (0.62) PTPN1HNF4AMEN1KMT2AMAPT
SCHEMBL6673496 0.90 MEN1 (0.62) PTPN1HNF4AMEN1KMT2AMAPT
SCHEMBL6677951 0.84 KDM4E (0.58) MEN1KMT2AMAPTALDH1A1TSHR
SCHEMBL6677957 0.84 KDM4E (0.58) MEN1KMT2AMAPTALDH1A1TSHR
SCHEMBL6673286 0.82 ABCB1 (0.55) MEN1KMT2AMAPTTDP1ALDH1A1
SCHEMBL6673290 0.82 ABCB1 (0.55) MEN1KMT2AMAPTTDP1ALDH1A1
SCHEMBL6674560 0.81 LTC4S (0.45) PTPN1HNF4AMEN1KMT2AMAPT
SCHEMBL6674556 0.81 LTC4S (0.45) PTPN1HNF4AMEN1KMT2AMAPT
SCHEMBL7532475 0.80 PTPN1 (0.58) PTPN1HNF4APTGS2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1289936-B1 SUBSTITUTED STILBENES AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2004-10-20 EP claimed
US-6479548-B2 P-(BENZOYLAMINO)STILBENE DERIVATIVES TELIK, INC. 2002-11-12 US claimed
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US claimed
EP-1289936-B1 SUBSTITUTED STILBENES AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2004-10-20 EP disclosed
US-6479548-B2 P-(BENZOYLAMINO)STILBENE DERIVATIVES TELIK, INC. 2002-11-12 US disclosed
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers SLC2A1, SLC2A8, SLC2A2 PTPN1 1380/4885HNF4A 425/4885PTGS2 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.